Updates

Ref: BCIL/SE/2026/56 August 06, 2026 To, To, The Secretary, The Manager, BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Limited, Dalal Street, Exchange Plaza, C-1, G Block, Bandra-Kurla, Mumbai - 400 001 Complex, Bandra (East), Mumbai – 400 051 Scrip Code: 531719 Symbol: BHAGCHEM Sub: Investor Presentation Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith Investors Presentation on the Financial Highlights for the quarter ended June 30, 2026. The copy of the same is also available on the website of the Company i.e. www.bhagirad.com Kindly take the same on record and display on the website of your exchange. Thanks & Regards, For Bhagiradha Chemicals and Industries Limited, Sharanya. M Company Secretary & Compliance Officer M. No: F13842 Bhagiradha Chemicals & Industries Limited Q1 FY27 InvestorPresentation Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Bhagiradha Chemicals and Industries Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offeringdocument containing detailed informationabout the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of,or any omissionfrom,this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows,the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections Q1 FY27 Results Highlights Q1FY27 Consolidated Financial Highlights - Highest - Ever Quarterly Performance Revenue From Operations EBITDA PAT Highest - Ever Quarterly Performance Rs. In Crores Volumes: +58% +240% • Volumes increased due to better demand scenario, new 195.0 molecule launches, customer additions, and the ramp-up 30.5 +235.0% at Bheema Fine Chemicals. 158.1 140.1 Price Realizations: 123.8 13.3 114.0 19.4 • Realisations improved, driven by a better product mix, 15.1 13.7 overall pricing improvement of the product basket, and 9.0 5.5 4.0 4.6 4.1 higher sales of mid- and high-value products. Revenue: Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 • Revenue growth was driven by both higher volumes and improved realisations, supported by new product contributions. Gross Margin (%) EBITDA Margin (%) PAT Margin (%) Gross Margins: • Gross margin expanded, supported by better 503 bps realisations, a favourable product mix, process improvements, backward integration, and broadly stable 43.0% prices for key raw materials. 38.9% 38.6% 839 bps 33.5% 34.8% EBITDA: 15.7% 362 bps • EBITDA improved on higher capacity utilisation, a richer 12.0% 12.3% product mix, and operating leverage, which lowered 10.7% 6.8% fixed costs per unit. 7.3% 3.2% 3.9% 4.0% PAT: 2.6% • PAT improved, driven by stronger operating efficiency, despite higher depreciation and finance costs associated Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 with the ramp-up of Bheema Fine Chemicals. Consolidated Profit & Loss Statement Particulars (Rs. In Cr.) Q1FY27 Q1FY26 YoY Q4FY26 QoQ FY26 Revenue From Operations 195.0 123.8 58% 158.1 23% 535.9 Cost of Raw Materials Consumed 119.8 82.3 96.6 335.2 Gross Profit 75.2 41.5 81% 61.5 22% 200.8 Gross Profit Margin (%) 38.6% 33.5% 38.9% 37.5% Employee Benefit Expenses 14.7 11.4 14.6 49.5 Other Expenses 30.0 21.1 27.4 94.2 EBITDA 30.5 9.0 240% 19.4 57% 57.1 EBITDA Margin (%) 15.7% 7.3% 12.3% 10.7% Depreciation & Amortization 8.3 3.9 8.2 20.9 EBIT 22.2 5.1 333% 11.2 98% 36.2 Interest Expense 6.4 3.3 7.0 17.5 Other Income 1.8 0.6 0.7 2.4 Exceptional Gain/Loss 0.0 0.0 0.0 0.0 Profit Before Tax 17.5 2.5 4.8 21.1 Tax Expense 4.2 -1.5 0.7 2.9 Profit After Tax 13.3 4.0 235% 4.1 227% 18.2 Profit After Tax Margin (%) 6.8% 3.2% 2.6% 3.4% Management Commentary Commenting on the performance Mr. A. Arvind Kumar, Executive Director & CEO said: “Q1 FY27 marked a strong start to the year, with robust revenue growth driven by higher volumes, improved realisations, and a favourable product mix. During the quarter, we introduced four new molecules, largely in the mid- to high-value segments, which contributed meaningfully to the Company’s growth trajectory. Margins improved on both a year-on-year and sequential basis, supported by better realisations and operating leverage. Raw-material prices remained broadly stable, although select crude-linked inputs witnessed an increase due to the ongoing geopolitical developments in West Asia. The Bheema Fine Chemicals facility continued to ramp up well during the quarter, with capacity utilisation nearly doubling compared with Q4 FY26. The facility remains focused on mid- and high-value molecules, with an increasing emphasis on expanding the contribution from high-value products. Going forward, we expect the progressive ramp-up at Bheema and the introduction of additional mid- to high-value molecules to support stronger growth. At the existing Bhagiradha facility, we are gradually reducing the share of low-margin products and redeploying the available capacity towards better margin products. This strategic shift in the product portfolio across both facilities is expected to improve the quality of revenues and support sustainable growth in profitability. Operationally, we continue to upgrade processes, adopt new technologies and debottleneck few capacities. This will improve overall efficiency. These initiatives are expected to enhance throughput, improve utilisation levels and contribute further to margin expansion. With the ramp-up at Bheema, continued portfolio optimization and ongoing operational improvements, the Company remains well positioned to deliver healthy growth in both revenue and profitability during FY27.” Company Overview Bhagiradha at a Glance 30+ years Establishment Product Portfolio Manufacturing Faci [Showing first 8,000 characters — download PDF for full document]